Your session is about to expire
← Back to Search
ExoFlo for COVID-19
Study Summary
This trial will test the safety and efficacy of ExoFlo, a bone marrow mesenchymal stem cell-derived extracellular vesicle, as treatment for mild-moderate COVID-19.
- COVID-19
- Coronavirus
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 102 Patients • NCT04493242Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this research involve test subjects that are senior citizens?
"The age limit for this clinical trial is 85 years old. So long as they are above 18, any patient can be enrolled."
When can US patients expect to have access to ExoFlo?
"While there is evidence that ExoFlo is safe, it only received a 2 because this Phase 2 trial has not yet yielded data supporting efficacy."
Are patients able to sign up for this test right now?
"Unfortunately, this specific study is not looking for any new participants as of now. According to the clinicaltrials.gov website, recruitment for this trial ended on August 23rd, 2022. Although this particular research project isn't presently recruiting, there are 1130 other studies that currently are."
How many research facilities are currently running this trial?
"Right now, potential participants can choose from 6 different clinical trial sites. The locations are Fullerton, Sheffield and Austin plus 3 other cities. If you want to take part in this study, try to pick a location that is close to minimize travel."
How can I sign up to take part in this research project?
"Up to 30 people suffering from covid-19 will be accepted into this trial, provided they are willing to commit to the study's procedures and are available for its entirety. In order to qualify, patients must also meet the following additional requirements: being between 18 and 85 years old, having a RT-PCR SARS-CoV-2 test in the last 3 days that came back positive, being 10 days or less from acute COVID-19 symptom onset, not being at high risk for progression to severe COVID=19, having received their final dose of vaccination more than 28 days ago (if applicable), being on <"
Share this study with friends
Copy Link
Messenger